RecruitingPhase 2NCT07755410

A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

Sponsor

Alkermes, Inc.

Enrollment

312 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Attention Deficit Disorder With Hyperactivity (ADHD)

Summary

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ALKS 7290 and a drug called Placebo for people with attention deficit disorder with hyperactivity (adhd). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGALKS 7290

ALKS 7290 tablets taken daily, orally, for 4 weeks

DRUGPlacebo

Placebo capsule taken daily

Locations(2)

Alkermes Investigator Site

Chino, California, United States

Alkermes Investigator Site

Maitland, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07755410

Related Trials

Pai.ACT - An Artificial Intelligence Driven Chatbot Assisted ACT (Full Scale RCT)

NCT06779422

Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

NCT07487155

Behavioral Parent Training With and Without AI Support for Children With Disruptive Behaviors

NCT074692151 location

Investigating Mediodorsal Thalamus Representations Underlying Human Cognitive Flexibility

NCT072176521 location

External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms

NCT072145451 location